Tvardi Therapeutics (TVRD) Revenue (2013 - 2025)
Tvardi Therapeutics (TVRD) posted Revenue of $2.6 million for Q1 2025, up 76.56% sequentially from $1.5 million in Q4 2024, and up 20.33% YoY from $2.1 million in Q1 2024.
Tvardi Therapeutics (TVRD) Revenue (2013 - 2025) Analysis & Trends
Tvardi Therapeutics has reported Revenue for 13 years, with the latest figure at $2.6 million in Q1 2025.
- Quarterly Revenue rose 20.33% year-over-year to $2.6 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $7.6 million (down 55.3% YoY) and the FY2024 annual result came in at $7.1 million, down 65.96% from the prior year.
- Revenue grew to $2.6 million in Q1 2025 per TVRD's latest filing, from $1.5 million in the prior quarter.
- Over five years, Revenue peaked at $23.0 million in Q2 2022 and troughed at $821000.0 in Q4 2021.
- A 5-year average of $6.0 million and a median of $3.1 million in 2022 frame the typical range for Revenue.
- The sharpest annual moves came in 2021 and 2022: Revenue slumped 99.26% in 2021, then jumped 297.2% in 2022.
- Over 5 years, Revenue stood at $821000.0 in 2021, then surged by 297.2% to $3.3 million in 2022, then decreased by 7.88% to $3.0 million in 2023, then plunged by 51.56% to $1.5 million in 2024, then jumped by 76.56% to $2.6 million in 2025.
- According to Business Quant data, Revenue over the past three periods registered $2.6 million, $1.5 million, and $2.6 million for Q1 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 2.57 Mn |
| Dec 31, 2024 | 1.46 Mn |
| Sep 30, 2024 | 2.56 Mn |
| Jun 30, 2024 | 991,000.00 |
| Mar 31, 2024 | 2.14 Mn |
| Dec 31, 2023 | 3.00 Mn |
| Sep 30, 2023 | 4.87 Mn |
| Jun 30, 2023 | 6.93 Mn |
| Mar 31, 2023 | 6.17 Mn |
| Dec 31, 2022 | 3.26 Mn |
| Sep 30, 2022 | 10.81 Mn |
| Jun 30, 2022 | 23.00 Mn |
| Mar 31, 2022 | 4.79 Mn |
| Dec 31, 2021 | 821,000.00 |
| Sep 30, 2021 | 20.27 Mn |
| Mar 31, 2021 | 1.94 Mn |
| Dec 31, 2020 | 111.55 Mn |
| Sep 30, 2020 | 9.27 Mn |
| Jun 30, 2020 | 5.63 Mn |
| Mar 31, 2020 | 8.09 Mn |